FDA accepts Mesoblast’s latest BLA for paediatric GvHD cell therapy
Mesoblast has announced that the US Food and Drug Administration (FDA) has accepted a resubmitted biologics license application (BLA) for…
Mesoblast has announced that the US Food and Drug Administration (FDA) has accepted a resubmitted biologics license application (BLA) for…
Bristol Myers Squibb has announced that the European Medicines Agency (EMA) will begin a review of its application covering the…
Atara Biotherapeutics has announced that the US Food and Drug Administration (FDA) has awarded a priority review for its biologics…
Delix Therapeutics is planning to initiate two studies to evaluate patients with major depression investigating its lead neuroplastogen candidate, DLX-001,…
Johnson & Johnson (J&J) has announced that it has completed the $1.25bn acquisition of Yellow Jersey Therapeutics. Through the all-cash…
Eisai and Biogen must now brace for competition as the US Food and Drug Administration (FDA) has greenlit Eli Lilly’s…
Months after sending warning letters to pharma manufacturers challenging patents targeting drugs for diabetes, weight loss, and asthma, the Federal…
Merck & Co (MSD) has announced that its ongoing agreement with Orion Corporation for the co-development and co-commercialisation of opevesostat…
While the playground for drug discovery and development has changed, the name of the game for pharma and biotechs remains…
Alnylam Pharmaceuticals saw shares of its stock jump by 32% after sharing positive topline results for a late-stage study of…